SHAREHOLDER ALERT: Investors With More Than $50,000 In Losses From Investments In Amarin Corporation Plc Are Encouraged To Contact Wolf Haldenstein Before The January 3, 2014 Lead Plaintiff Deadline
The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Amarin Corporation plc (“Amarin” or the “Company”) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding prospective FDA approval of the proposed “ANCHOR” indication for the Company’s Vascepa drug.
On October 16, 2013, the NASD halted trading in Amarin common stock while the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee considered results of the ANCHOR study, which questioned the drug’s efficacy in treating severe cardiovascular events, and voted 9-2 to reject the New Drug Application for the ANCHOR indication of Vascepa.
On this news, and upon resumption of trading on October 17, 2013, Amarin common stock declined over 60% from $5.17 per share to $2.01 per share on heavy trading volume.
Wolf Haldenstein has represented individual and institutional investors for many years, serving as lead counsel in numerous cases in United States federal and state courts. Please visit the Wolf Haldenstein website ( http://www.whafh.com) for more information about the firm.Please contact us no later than January 3, 2014 if you own Amarin securities and wish to discuss this matter with us, or have any questions concerning your rights and interests: Gregory M. Nespole, Esq.Wolf Haldenstein Adler Freeman & Herz LLP270 Madison AvenueNew York, New York 10016 Phone Numbers:(800) 575-0735(212) 545-4657(917) 515-6161 Email: Classmember@whafh.com or email@example.com and please reference “Amarin Investigation.” Attorney Advertising
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts